VIDAS ToRC panel
Serenity throughout pregnancy
The VIDAS ToRC panel includes 9 automated testsfor the screening and diagnosis of toxoplasmosis, rubella and cytomegalovirus (CMV) infections.
- Complete solution
- Proven high performance of IgG avidity tests
- Cost-effective solution for small routine and confirmation testing
- Description
- Technical details
Description
The VIDAS® ToRC panel is a complete solution for the diagnosis and follow-up of the most important materno-fetal infections in pregnant women and newborns. Toxoplasmosis, Rubella and Cytomegalovirus (ToRC) infections are generally benign diseases. However when women are infected during pregnancy, consequences for the fetus can be dramatic. Our value-added IgG avidity tests help distinguish between recent and past infection, thus reducing the number of amniocenteses, and avoiding unnecessary treatment and stress for the future mothers.
A complete solution
- 3 markers for accurate diagnosis
IgG: IgGs are widely used to determine the presence of specific immunity.
IgM: If IgMs appear earlier than IgGs, they also disappear earlier. This makes IgMs an early and sensitive marker of acute infection.
IgG avidity:
IgGs are initially of low avidity, but will mature to high avidity a few months after primary infection. A high IgG avidity index thus allows to rule out recently-acquired infection.
- The VIDAS® ToRC solution
| Toxoplasmosis | Rubella | Cytomegalovirus |
|---|---|---|
| VIDAS TOXO IgG II | VIDAS RUB IgG | VIDAS CMV IgG |
| VIDAS TOXO IgM | VIDAS RUB IgM | VIDAS CMV IgM |
| VIDAS TOXO Competition* | VIDAS CMV IgG Avidity II | |
| VIDAS TOXO IgG Avidity |
Highly performant IgG avidity tests
VIDAS CMV IgG Avidity II
VIDAS CMV IgG Avidity II is a simple technique which enables weak avidity antibodies to be differentiated from high avidity antibodies. The detection of high avidity antibodies is a strong indication of a primary infection of more than 3 months, whereas the detection of weak avidity antibodies is a strong indication of a primary infection of less than 3 months.
A study conducted to assess VIDAS CMV IgG avidity II maturation kinetics on 135 sequential samples from 31 patients1 confirmed a very good correlation to clinical diagnosis:
- No misclassification of recent infections (< 3 months)
- No misclassification of past infections (> 3 months)
- Best correlation over time from onset of infection compared to other commonly-used assays
- Most regular avidity maturation pattern
VIDAS TOXO IgG Avidity
VIDAS TOXO IgG Avidity is a simple technique which enables weak avidity antibodies to be differentiated from high avidity antibodies. The detection of high avidity antibodies is a strong indication of a primary infection dating back more than 4 months.
- Only FDA cleared Toxo IgG avidity test
- Best performance for the exclusion of primary infection in patients with IgM and IgG positive results compared to other avidity assays2,3
- The VIDAS system holds a reference position in the field of toxoplasmosis serology
Ease of use and cost-effectiveness
- Single-dose, ready-to-use tests
- Performed on the automated VIDAS immunoanalyzers, recognized worldwide for their flexibility, ease-of-use, reliability and 24/7 availability
- Small packaging volumes
- Ideal solution for small routine, confirmation of positive IgM, and IgG avidity testing
| VIDAS ToRC panel | ||||||
|---|---|---|---|---|---|---|
| Parameter | Reference | Tests/kit | Sample type | Sample volume | Time to result | Calibration frequency |
| CMV IgG | 30 204 | 60 | Serum | 100 µL | 40 minutes | 14 days |
| CMV IgM | 30 205 | 30 | Serum | 100 µL | 60 minutes | 14 days |
| CMV IgG Avidity II | 41 3557 | 30 | Serum | 2 x 100 µL | 40 minutes | No calibration |
| RUB IgG II | 30 221 | 60 | Serum, plasma | 100 µL | 40 minutes | 14 days |
| RUB IgM | 30 214 | 30 | Serum | 100 µL | 60 minutes | 14 days |
| TOXO IgG II | 30 210 | 60 | Serum, plasma | 100 µL | 40 minutes | 14 days |
| TOXO IgG Avidity | 30 222 | 30 | Serum, plasma | 2 x 100 µL | 40 minutes | No calibration |
| TOXO IgM | 30 202 | 60 | Serum | 100 µL | 40 minutes | 14 days |
| TOXO Competition | 30 211 | 60 | Serum, plasma | 125 µL | 40 minutes | 14 days |








